Danaher's revenue outlook cut, biotech miss overshadow profit forecast raise

Danaher raised its annual profit forecast on Tuesday, but shares fell nearly 12% in premarket trading after the life sciences firm ​trimmed its core revenue growth outlook and reported weaker-than-expected revenue ‌in its biotechnology business.